title: [The in vivo antitumor activity of murine liver tumor vaccine expressing MIP-1alpha].
abstract: OBJECTIVE
  To observe the in vivo antitumor activity of murine liver tumor vaccine expressing MIP-1alpha mediated by recombinant adenoviral vector.
  
  
  METHODS
  The infection efficacy was measured by GFP expression 48 hours after infection of Hepa1-6, and the number of cells was counted daily for 14 days. 5 x 10(6) modified Hepa1-6 cells were inoculated subcutaneously to C57BL/6 mice and the tumor-free animals were rechallenged by 2 x 10(6) wild-type Hepa1-6 cells or syngenic EL4 cells four weeks later. The tumor volume was measured twice a week.
  
  
  RESULTS
  Adenoviral vectors could efficiently infect Hepa1-6 cells in vitro, and the in vitro growth rate of AdmMIP-1alpha modified Hepa1-6 cells was not affected; however the in vivo tumorigenicity was significantly decreased, compared with that of control vector modified Hepa1-6. Rechallenge of the tumor-free mice four weeks after administration of AdmMIP-1alpha with the parental Hepa1-6 cells resulted in significant inhibition of tumor growth, but there was no significant difference when rechallenged with EL4.
  
  
  CONCLUSIONS
  The liver cancer cells expressing mMIP-1alpha mediated by recombinant adenoviral vector decrease tumorigenicity and elicit specific immunological protection, and could be used as an effective liver tumor vaccine.
authors.affiliation: Tumor Immunology and Biotherapy Center, Eastern Institute of Hepatobiliary Surgery, Second Military Medical University, Shanghai 200438, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Yang
authors.forename: Guangshun
authors.initials: G
authors.lastname: Yang
authors.forename: Lixin
authors.initials: L
authors.lastname: Wei
authors.forename: Fengqi
authors.initials: F
authors.lastname: Jia
authors.forename: Weifeng
authors.initials: W
authors.lastname: Wang
authors.forename: Mengchao
authors.initials: M
authors.lastname: Wu
authors.forename: Yajun
authors.initials: Y
authors.lastname: Guo
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D015316:Genetic Therapy; D008114:Liver Neoplasms, Experimental / Q000628:therapy*; D019402:Macrophage Inflammatory Proteins / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D019402:Macrophage Inflammatory Proteins; D014614:Vaccines, Synthetic